TP53 and diffuse large B-cell lymphoma: A phase Ib dose-escalation trial in R/R DLBCL, stratified by TP53 status, CREB3L1 expression, and the revised International Prognostic Index [35,38], would clarify feasibility and enable combination with PD-1 blockade to determine whether the observed innate activation augments adaptive immunity.